| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
A cholinesterase inhibitor with a slightly longer duration of action than neostigmine. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants. [PubChem] |
| Indication |
For the treatment of myasthenia gravis. |
| Pharmacology |
Pyridostigmine is a parasympathomimetic and a reversible cholinesterase inhibitor. Since it is a quaternary amine, it is poorly absorbed in the gut and doesn't cross the blood-brain barrier. Pyridostigmine has a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Biotransformation |
Hydrolysis by cholinesterases and by liver. |
| Absorption |
Poorly absorbed from the GI tract with an oral bioavailability of 7.6 +/- 2.4%. |
| Half Life |
3 hours following oral administration. |
| References |
| • |
Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA: Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1294-8.
[Pubmed]
|
|
| External Links |
|